MCID: ECL001
MIFTS: 52

Eclampsia

Categories: Cardiovascular diseases, Nephrological diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Eclampsia

MalaCards integrated aliases for Eclampsia:

Name: Eclampsia 12 20 29 54 44 15 70 32
Eclampsia in Puerperium 12 70
Eclampsia, Postpartum 12
Postpartum Eclampsia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13593
MeSH 44 D004461
NCIt 50 C87167
SNOMED-CT 67 156111007
ICD10 32 O15 O15.2
UMLS 70 C0013537 C0156678

Summaries for Eclampsia

Disease Ontology : 12 A pre-eclampsia characterized by the presence of seizures.

MalaCards based summary : Eclampsia, also known as eclampsia in puerperium, is related to mild pre-eclampsia and preeclampsia/eclampsia 1, and has symptoms including seizures An important gene associated with Eclampsia is STOX1 (Storkhead Box 1), and among its related pathways/superpathways are Signaling events mediated by VEGFR1 and VEGFR2 and Glypican 1 network. The drugs Methyldopa and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include placenta, endothelial and kidney, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 73 Eclampsia is the onset of seizures (convulsions) in a woman with pre-eclampsia. Pre-eclampsia is a... more...

Related Diseases for Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 563)
# Related Disease Score Top Affiliating Genes
1 mild pre-eclampsia 32.2 VEGFA STOX1 PGF PAPPA FLT1 ENG
2 preeclampsia/eclampsia 1 32.1 SERPINC1 PEE1
3 severe pre-eclampsia 32.1 VEGFA SERPINC1 PGF PAPPA HLA-G
4 hypertensive encephalopathy 30.9 VEGFA PGF FLT1 F2
5 hellp syndrome 30.8 VEGFA THBD SERPINC1 PGF MTHFR FLT1
6 peripartum cardiomyopathy 30.7 VEGFA PGF FLT1
7 gestational trophoblastic neoplasm 30.5 PGF PAPPA OXT HLA-G
8 disseminated intravascular coagulation 30.4 THBD SERPINC1 F2
9 chorioamnionitis 30.4 VEGFA OXT FLT1
10 thrombotic microangiopathy 30.4 VEGFA THBD
11 pulmonary edema 30.3 SERPINC1 OXT F2
12 retinal vascular disease 30.2 VEGFA PGF MTHFR FLT1
13 oligohydramnios 30.1 PGF PAPPA OXT
14 thrombophilia 30.1 THBD SERPINC1 MTHFR F2
15 antiphospholipid syndrome 30.0 THBD SERPINC1 MTHFR F2
16 placenta praevia 30.0 PGF PAPPA OXT F2
17 purpura 30.0 THBD SERPINC1 F2
18 placental insufficiency 30.0 VEGFA SERPINC1 PGF PAPPA FLT1 F2
19 intracranial hypertension 29.9 SERPINC1 MTHFR F2
20 microvascular complications of diabetes 5 29.8 VEGFA PGF FLT1
21 ectopic pregnancy 29.7 VEGFA PGF PAPPA FLT1
22 thrombophlebitis 29.7 SERPINC1 MTHFR F2
23 homocysteinemia 29.7 THBD SERPINC1 MTHFR F2
24 vascular disease 29.7 VEGFA THBD SERPINC1 MTHFR F2 ENG
25 thrombophilia due to activated protein c resistance 29.6 THBD SERPINC1 MTHFR F2
26 retinal vein occlusion 29.6 VEGFA SERPINC1 MTHFR F2
27 papilledema 29.6 VEGFA SERPINC1 F2
28 antithrombin iii deficiency 29.6 SERPINC1 MTHFR F2
29 thrombophilia due to thrombin defect 29.5 THBD SERPINC1 MTHFR F2
30 placental abruption 29.5 THBD SERPINC1 PGF PAPPA MTHFR HLA-G
31 placenta disease 29.5 VEGFA SERPINC1 PGF PAPPA OXT MTHFR
32 pre-eclampsia 29.5 VEGFA THBD TAC3 STOX1 SERPINC1 PGF
33 hepatic infarction 29.4 SERPINC1 F2
34 thrombosis 29.4 THBD SERPINC1 MTHFR F2
35 portal vein thrombosis 29.4 SERPINC1 MTHFR F2
36 intracranial hypotension 29.4 SERPINC1 F2
37 placenta accreta 29.3 VEGFA PGF PAPPA OXT FLT1
38 budd-chiari syndrome 29.3 SERPINC1 MTHFR F2
39 pulmonary hypertension 29.3 VEGFA THBD SERPINC1 F2 ENG
40 central retinal vein occlusion 29.3 VEGFA SERPINC1 MTHFR F2
41 protein s deficiency 29.3 THBD SERPINC1 MTHFR F2
42 protein c deficiency 29.3 THBD SERPINC1 MTHFR F2
43 stroke, ischemic 29.2 THBD SERPINC1 MTHFR F2 ENG
44 diabetes mellitus 29.2 VEGFA THBD SERPINC1 PGF PAPPA MTHFR
45 sagittal sinus thrombosis 29.2 THBD SERPINC1 F2
46 bilirubin metabolic disorder 29.2 VEGFA SERPINC1 OXT F2
47 lipoprotein quantitative trait locus 29.1 VEGFA THBD PGF MTHFR F2 ENG
48 homocystinuria 29.1 THBD SERPINC1 MTHFR
49 atrial heart septal defect 29.0 SERPINC1 MTHFR F2
50 pulmonary embolism 29.0 THBD SERPINC1 MTHFR F2

Graphical network of the top 20 diseases related to Eclampsia:



Diseases related to Eclampsia

Symptoms & Phenotypes for Eclampsia

UMLS symptoms related to Eclampsia:


seizures

MGI Mouse Phenotypes related to Eclampsia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10 CORIN ENG F2 FLT1 NOSTRIN OXT
2 growth/size/body region MP:0005378 9.97 CORIN ENG F2 FLT1 INHBB MTHFR
3 homeostasis/metabolism MP:0005376 9.83 CORIN ENG EPHX1 F2 FLT1 HLA-G
4 integument MP:0010771 9.28 CORIN ENG F2 INHBB MTHFR OXT

Drugs & Therapeutics for Eclampsia

Drugs for Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 260)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyldopa Approved Phase 4 555-30-6 38853
2
Azithromycin Approved Phase 4 83905-01-5 55185 447043
3
Nitric Oxide Approved Phase 4 10102-43-9 145068
4
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
5
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
6
Clonidine Approved Phase 4 4205-90-7 2803
7
Captopril Approved Phase 4 62571-86-2 44093
8
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
9
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
10
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
11
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
12
Enalaprilat Approved Phase 4 76420-72-9 6917719
13
Metformin Approved Phase 4 657-24-9 14219 4091
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Ibuprofen Approved Phase 4 15687-27-1 3672
16
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
17
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
18
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
19
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
20
Phenylephrine Approved Phase 4 59-42-7 6041
21
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
22 Anti-Bacterial Agents Phase 4
23 diuretics Phase 4
24 isosorbide-5-mononitrate Phase 4
25 Hormone Antagonists Phase 4
26 Angiotensin-Converting Enzyme Inhibitors Phase 4
27 Hypoglycemic Agents Phase 4
28 Estrogens Phase 4
29 11-hydroxyprogesterone Phase 4
30 Estrogen Antagonists Phase 4
31 17 alpha-Hydroxyprogesterone Caproate Phase 4
32 Estrogen Receptor Antagonists Phase 4
33 Caproate Phase 4
34 Progestins Phase 4
35 Sodium Channel Blockers Phase 4
36 Anesthetics, Local Phase 4
37 Diuretics, Potassium Sparing Phase 4
38 Vaccines Phase 4
39 Anticonvulsants Phase 4
40 Cardiotonic Agents Phase 4
41 Protective Agents Phase 4
42 Respiratory System Agents Phase 4
43 Nasal Decongestants Phase 4
44 Mydriatics Phase 4
45
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
46
Misoprostol Approved Phase 3 59122-46-2 5282381
47
Carbetocin Approved, Investigational Phase 3 37025-55-1 71715 16681432
48
Dexmedetomidine Approved, Vet_approved Phase 2, Phase 3 113775-47-6 68602 5311068
49
Atorvastatin Approved Phase 3 134523-00-5 60823
50
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840

Interventional clinical trials:

(show top 50) (show all 549)
# Name Status NCT ID Phase Drugs
1 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
2 Effectiveness Of Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia: Randomized Placebo-Controlled Clinical Trial Unknown status NCT01361425 Phase 4 methildopa;placebo
3 Low Dose Calcium Supplementation to Prevent Preeclampsia: a Cluster Randomized Study Unknown status NCT02338687 Phase 4
4 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Unknown status NCT02911701 Phase 4 Acetaminophen;Ibuprofen
5 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Unknown status NCT02920593 Phase 4 Vitamin D3
6 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Among Egyptian Primigravidae: a Randomized Controlled Trial Unknown status NCT03233880 Phase 4 Azithromycin 1gm
7 Oral Nifedipine Versus Labetalol in Treatment of Postpartum Hypertension Unknown status NCT03449277 Phase 4 Oral Tablet
8 Cardiovascular Performance and Autonomic Reactivity in Formerly Preeclamptic Women With a Contracted Plasma Volume (CAPACITY Trial) Unknown status NCT00117546 Phase 4 alpha methyldopa
9 Continuation Versus Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Unknown status NCT03318211 Phase 4 Magnesium Sulfate
10 Effect of Administering Intravenous Magnesium Sulfate Heptahydrate (MgSO4•7H2O) on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients in 3rd Trimester of Pregnancy Unknown status NCT03237000 Phase 4 MgSO4
11 An Open-label Randomized-Controlled Trial of Early Screening Test for Pre-eclampsia and Growth Restriction Completed NCT03674606 Phase 4 Low dose aspirin
12 Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
13 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4 Aspirin;Placebo
14 A Randomized-controlled Trial to Assess the Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy Completed NCT02891174 Phase 4 Ibuprofen;Acetaminophen
15 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients Completed NCT01972659 Phase 4 placebo;Magnesium Sulphate;sugammadex
16 Efficacy and Safety of One Gram Versus Two Grams Intravenous Maintenance Dose of Magnesium Sulfate in Women With Severe Pre-eclampsia: a Randomized Clinical Trial. Completed NCT03164304 Phase 4 Magnesium Sulfate
17 Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
18 Ethnic Differences in Anti-Hypertensive Medication Response Among Pregnant and Postpartum Patients Completed NCT03506724 Phase 4 Nifedipine;Labetalol
19 Treatment Approaches to Preeclampsia Completed NCT01030627 Phase 4
20 Adding Magnesium Sulphate to Epidural Levobupivacaine in Elective Caesarian Section for Patients With Preeclampsia Completed NCT02699827 Phase 4 Levobupivacaine hydrochloride;Magnesium sulphate;Saline 0.9%
21 Randomized Trial of Magnesium Sulfate in Obese Preeclamptic Women Completed NCT02835339 Phase 4 Magnesium sulfate 4g loading dose, 1g/hr infusion;Magnesium sulfate 6g loading dose, 2g/hr infusion
22 Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy Completed NCT01912677 Phase 4 Nifedipine;Labetalol;Methyldopa
23 Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
24 Randomized Clinical Trial for Effectiveness of Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
25 A Randomized Open-label Study to Compare the Clinical Outcomes and Magnesium Serum Concentrations Obtained in the Treatment of Severe Preeclampsia With a Repeat Bolus Intravenous Magnesium Sulfate Regimen Administered With the Springfusor Infusion Pump to a Continuous Intravenous Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
26 Randomized Controlled Trial of Nitric-oxide Donor (NOD) Isosorbide Mononitrate (IMN) Versus Placebo for Induction of Labor in Pregnancies Complicated by Preeclampsia Completed NCT03171480 Phase 4 Monoket Pill
27 Personalized Hemodynamically Guided Antihypertensive Treatment in Pregnant Women With Mild to Moderate Hypertension: a Randomized Controlled Trial Recruiting NCT02531490 Phase 4 Labetalol;Nifedipine;Methyldopa
28 The Effect of 81mg vs 162mg ASA for Preeclampsia Prevention in Obese Women at High Risk for Developing Preeclampsia Recruiting NCT03735433 Phase 4 162mg aspirin dose
29 A Randomized Controlled Trial Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period Recruiting NCT04236258 Phase 4 NIFEdipine ER;Enalapril
30 Effect of Non-steroidal Anti-inflammatory Use on Blood Pressure in Women With Hypertensive Disorders of Pregnancy: A Randomized Open Label Trial Recruiting NCT03824119 Phase 4 Ibuprofen 600 mg
31 Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus Recruiting NCT03570632 Phase 4 Metformin
32 Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor Recruiting NCT04392375 Phase 4 Nifedipine 30 MG;Placebos
33 Aspirin to Prevent Cardiac Dysfunction in Preeclampsia Recruiting NCT04479072 Phase 4 Aspirin 81 mg;Placebo
34 Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia Recruiting NCT04797949 Phase 4 Low-dose aspirin
35 Efficacy of 17-Hydroxyprogesterone Caproate in Expectantly Managed Early-onset Preeclampsia: A Randomized Controlled Study Recruiting NCT04077853 Phase 4 17 Hydroxyprogesterone Capronate
36 Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies--A Multicenter, Prospective, Open, Randomized, Controlled Clinical Trial Recruiting NCT04051567 Phase 4 Aspirin 100mg
37 A Prospective Randomized Clinical Research Trial Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 and Those Receiving Tdap Vaccinations at Week 36 Not yet recruiting NCT04424693 Phase 4 Tdap Vaccine Administration
38 The Effectiveness of Low-dose Aspirin on Preventing Pre-eclampsia in High-risks Pregnant Women Not yet recruiting NCT04656665 Phase 4 Aspirin
39 Lignocaine Nebulization for Attenuation of Intubation Stress Response in Patients With Severe Pre-eclampsia: a Prospective Double-blinded Placebo-controlled Trial Not yet recruiting NCT04441073 Phase 4 Lignocaine;Placebo
40 A Prospective Muti-center Study of Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort Not yet recruiting NCT04631627 Phase 4 Aspirin
41 Impact of Vasopressor Administration on Maternal and Neonatal Outcomes in Women With Pre-eclampsia Terminated NCT02025426 Phase 4 Phenylephrine;Ephedrine
42 Effectiveness and Safety of 1g/Hour vs. 2g/Hour of Magnesium Sulfate Maintenance Dose for Eclampsia Prevention: Randomized Clinical Trial Terminated NCT02396030 Phase 4 Magnesium sulfate 50% - 1g/h;Magnesium sulfate 50% - 2g/h
43 Acute Control of Chronic Hypertension in Preeclampsia Terminated NCT03877692 Phase 4 Experimental dosing of labetalol
44 Acute Labetalol Use in Preeclampsia Randomized Trial Terminated NCT03872336 Phase 4 Experimental labetalol dose
45 A Pragmatic Randomized Study Comparing 81 mg Aspirin Versus 162 mg Aspirin in the Prevention of Preeclampsia During Pregnancy Withdrawn NCT04158830 Phase 4 Aspirin 81 mg Enteric Coated Tab - 1 tablet;Aspirin 81 mg Enteric Coated Tab - 2 tablets
46 Clinical Effect of Atenativ Treatment on Uterine Blood Flow and the Amount of Atenativ Needed to Maintain a Normal Antithrombin Lvels During Two Weeks in Early and Severe Preeclampsia Withdrawn NCT02278575 Phase 4 Atenativ
47 Treatment of Severe Hypertension During Pre-Eclampsia.A Preliminary Equivalence Study Between URAPIDIL and NICARDIPINE Unknown status NCT00409253 Phase 3 URAPIDIL (EUPRESSYL*);NICARDIPINE
48 Oral Nifedipine Versus IV Labetalol in Treatment of Severe Pre Eclampsia in Pregnancy Unknown status NCT03325348 Phase 2, Phase 3 Nifedipine 10 mg;Labetalol
49 Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial Unknown status NCT03262961 Phase 2, Phase 3 Sildenafil 20 MG;Placebo Oral Tablet
50 Combined Sonographic Examination and Placenta Protein 13 (PP13) to Compare the Risk for Development of Preeclampsia Among Among Pregnant Women With and Without a History of Preterm Delivery and Those Treated by Progesterone or Clexane Unknown status NCT00928213 Phase 2, Phase 3 Progesterone;Low molecular weight Heparin;No Drug

Search NIH Clinical Center for Eclampsia

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Magnesium Sulfate
Nitroglycerin

Cochrane evidence based reviews: eclampsia

Genetic Tests for Eclampsia

Genetic tests related to Eclampsia:

# Genetic test Affiliating Genes
1 Eclampsia 29

Anatomical Context for Eclampsia

MalaCards organs/tissues related to Eclampsia:

40
Placenta, Endothelial, Kidney, Thyroid, Ovary, Heart, Liver

Publications for Eclampsia

Articles related to Eclampsia:

(show top 50) (show all 15813)
# Title Authors PMID Year
1
Correlation between maternal plasma thrombomodulin and infant birth weight in hypertensive disorders of pregnancy. 54 61
19022800 2009
2
Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy. 61 54
15893867 2005
3
Absence of Factor V Leiden, thrombomodulin and prothrombin gene variants in Black South African women with pre-eclampsia and eclampsia. 54 61
12628278 2003
4
[Folic acid levels, homocysteine and polymorphism of methylenetetrahydrofolate reductase enzyme (MTHFR) in patients with pre-eclampsia and eclampsia]. 61 54
11268732 2001
5
Methylenetetrahydrofolate reductase polymorphisms are not a risk factor for pre-eclampsia/eclampsia in Australian women. 61 54
10965192 2000
6
Methylenetetrahydrofolate reductase 677 C --> T polymorphism, plasma folate, vitamin B(12) concentrations, and risk of preeclampsia among black African women from Zimbabwe. 61 54
10655155 2000
7
[Antithrombin-III in preeclampsia-eclampsia. Pilot study]. 54 61
9745197 1998
8
Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1. 54 61
9531039 1998
9
Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia. 61 54
8960994 1996
10
HLA-G deletion polymorphism and pre-eclampsia/eclampsia. 61 54
7547760 1995
11
Pregnancy induced hypertension and antithrombin-III. 61 54
8819656 1995
12
[Antithrombin ii in eclampsia: estimation of predictive value]. 54 61
1345066 1992
13
Reduced neuropathy target esterase in pre-eclampsia suppresses tube formation of HUVECs via dysregulation of phospholipid metabolism. 61
33184906 2021
14
Unusual thrombosis or pregnancy complications associated to ovarian cancers: two clinical cases. 61
31258012 2021
15
Risk of adverse maternal outcomes associated with prenatal exposure to moderate-severe depression compared with mild depression: A fellow-up study. 61
33548828 2021
16
Potential role of FoxO3a in the regulation of trophoblast development and pregnancy complications. 61
33811439 2021
17
Predictive value of 4-Hydroxyglutamate and miR-149-5p on eclampsia. 61
33582167 2021
18
Hippocampal network dysfunction as a mechanism of early-onset dementia after preeclampsia and eclampsia. 61
33130230 2021
19
Developing a core outcome set in interventions to prevent stillbirth: A systematic review on variations of outcome reporting. 61
33583657 2021
20
Outcome of pregnancies with marginal umbilical cord insertion. 61
31164018 2021
21
HDAC2-mediated proliferation of trophoblast cells requires the miR-183/FOXA1/IL-8 signaling pathway. 61
33164209 2021
22
Management of sellar and parasellar tumors becoming symptomatic during pregnancy: a practical algorithm based on multi-center experience and systematic literature review. 61
33200305 2021
23
Perinatal death audit and classification of stillbirths in two provinces in Papua New Guinea: A retrospective analysis. 61
33098672 2021
24
Recommendations for Pregnancy in Fanconi Anemia. 61
33798394 2021
25
Cardiovascular severe maternal morbidity in pregnant and postpartum women: development and internal validation of risk prediction models. 61
32946639 2021
26
The role of prenatal and perinatal factors in eating disorders: a systematic review. 61
32767123 2021
27
Maternal risk of hypertension 7-15 years after pregnancy: clues from the placenta. 61
32931608 2021
28
Impact of maternal infection with hepatitis B virus on pregnancy complications and neonatal outcomes for women undergoing assisted reproductive technology treatment: A population-based study. 61
33452707 2021
29
Placental pathology and neonatal outcomes in pre-eclampsia with gestational diabetes mellitus. 61
32627623 2021
30
Pregnancy After Kidney Transplantation. 61
33358422 2021
31
Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation. 61
33794058 2021
32
Aspirin to prevent pre-eclampsia. 61
33658298 2021
33
Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 35-37 weeks' gestation. 61
33073902 2021
34
Pernicious pregnancy: Type B aortic dissection in pregnant women. 61
33533078 2021
35
The safety and efficacy of supervised exercise on pregnant women with overweight/obesity: A systematic review and meta-analysis of randomized controlled trials. 61
33167074 2021
36
What do we know about the diagnosis and management of mirror syndrome? 61
33722118 2021
37
Preeclampsia before 26 weeks of gestation: Obstetrical prognosis for the subsequent pregnancy. 61
33221560 2021
38
Endometriosis and assisted reproductive techniques independently related to mother-child morbidities: a French longitudinal national study. 61
33388264 2021
39
Maternal and foetal placental vascular malperfusion in pregnancies with anti-phospholipid antibodies. 61
32864694 2021
40
Placental disorders of pregnancy in subsequent IVF pregnancies - a sibling cohort. 61
33468400 2021
41
Aspirin Prophylaxis During Pregnancy: A Systematic Review and Meta-Analysis. 61
33795180 2021
42
Hypertensive Disorders of Pregnancy and Subsequent Risk of Premature Mortality. 61
33706872 2021
43
Correlation of serum collectrin level and preeclampsia onset: A case control study. 61
32325273 2021
44
Environmental Exposure during Pregnancy: Influence on Prenatal Development and Early Life: A Comprehensive Review. 61
33735860 2021
45
Plasma angiotensin II levels in women with severe preeclampsia under magnesium sulfate regimen. 61
33249328 2021
46
Genetic association of ERAP1 and ERAP2 with eclampsia and preeclampsia in northeastern Brazilian women. 61
33762660 2021
47
Neuropathophysiology of preeclampsia and eclampsia: A review of cerebral hemodynamic principles in hypertensive disorders of pregnancy. 61
33310389 2021
48
Validation of the fullPIERS model for prediction of adverse outcomes in preeclampsia at a referral center. 61
33310390 2021
49
Cerebral perfusion pressure and autoregulation in eclampsia - a case control study. 61
33744176 2021
50
Prevalence of Hypertension Among Pregnant Women When Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines and Association With Maternal and Fetal Outcomes. 61
33787907 2021

Variations for Eclampsia

Expression for Eclampsia

Search GEO for disease gene expression data for Eclampsia.

Pathways for Eclampsia

Pathways related to Eclampsia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.3 VEGFA PGF FLT1
2 10.55 VEGFA SERPINC1 FLT1
3 10.43 F2 EPHX1
4
Show member pathways
10 VEGFA PGF FLT1

GO Terms for Eclampsia

Cellular components related to Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 VEGFA TAC3 SERPINC1 PGF PAPPA OXT
2 extracellular space GO:0005615 9.4 VEGFA THBD TAC3 SERPINC1 PGF PAPPA

Biological processes related to Eclampsia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.95 VEGFA STOX1 PGF FLT1 F2
2 angiogenesis GO:0001525 9.81 VEGFA PGF FLT1 ENG
3 positive regulation of protein phosphorylation GO:0001934 9.73 VEGFA PGF F2 ENG
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 VEGFA FLT1 F2
5 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.63 VEGFA PGF FLT1
6 response to hypoxia GO:0001666 9.62 VEGFA PGF MTHFR ENG
7 induction of positive chemotaxis GO:0050930 9.56 VEGFA PGF
8 positive regulation of angiogenesis GO:0045766 9.56 VEGFA PGF FLT1 ENG
9 hemostasis GO:0007599 9.54 THBD SERPINC1 F2
10 regulation of blood coagulation GO:0030193 9.52 SERPINC1 F2
11 negative regulation of fibrinolysis GO:0051918 9.49 THBD F2
12 negative regulation of platelet activation GO:0010544 9.48 THBD F2
13 positive regulation of mast cell chemotaxis GO:0060754 9.4 VEGFA PGF
14 sprouting angiogenesis GO:0002040 9.33 VEGFA PGF ENG
15 vascular endothelial growth factor signaling pathway GO:0038084 9.13 VEGFA PGF FLT1
16 female pregnancy GO:0007565 9.02 THBD TAC3 PAPPA OXT CORIN

Molecular functions related to Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.26 VEGFA SERPINC1 PGF F2
2 vascular endothelial growth factor receptor binding GO:0005172 9.16 VEGFA PGF
3 growth factor activity GO:0008083 8.92 VEGFA PGF INHBB F2

Sources for Eclampsia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....